

EBAC ACCREDITATION



The Course in **CARDIOVASCULAR RISK AND DYSLIPIDAEMIA: RISK REDUCTION BEFORE AND BEYOND STATINS** is accredited by the European Board for Accreditation in Cardiology (EBAC) for 6 CME credit/hour (s).

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters related to this Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Mylan in support of the Programme.

ITALIAN ACCREDITATION

ECM - FORMAZIONE

Provider Standard Nazionale

SITeCS - Società Italiana di Terapia Clinica e Sperimentale

Via Balzaretti, 7 - 20133 Milano - Tel. +39 02 49636373

e-mail: ecm@sitecs.it - www.sitecs.it

Evento RES N. 200-192494, crediti 4,9 – Piano Formativo 2017

Accreditato per 170 partecipanti per le seguenti figure – Medico Chirurgo, Cardiologia, Geriatria, Endocrinologia, Medicina Interna, Malattie Metaboliche, Diabetologia.

L'assegnazione dei crediti formativi sarà subordinata alla partecipazione effettiva all'intero programma formativo, alla verifica di apprendimento e al rilevamento delle presenze. L'attestato di partecipazione riportante il numero di crediti formativi verrà inviato per posta elettronica al partecipante dopo aver effettuato tali verifiche.

Organizing Secretariat:

Delos Communication srl

p.co Comola Ricci, 98 - 80122 Naples – Tel: +39 0817142129; Fax: +390817141472

email: info@deloscommunication.it – www.deloscommunication.it

The programme was made possible thanks to an unrestricted educational grant from



S.I.Te.C.S.

SOCIETÀ ITALIANA DI TERAPIA CLINICA E SPERIMENTALE

INTERNATIONAL WORKSHOP

CARDIOVASCULAR RISK AND DYSLIPIDAEMIA: RISK REDUCTION BEFORE AND BEYOND STATINS

Naples - 2017, June 3-4 - Hotel Royal Continental

Chairs

A.L. Catapano and L. Tokgözoğlu



This meeting is endorsed by the European Atherosclerosis Society



SATURDAY, JUNE 3

9.00 – 9.30	Registration
9.30 – 10.00	Introduction to the european guidelines <i>A.L. Catapano - Italy</i>
10.00 – 10.30	Lifestyle intervention <i>V. Barrios - Spain</i>
10.30 – 11.00	Role of nutraceuticals <i>A.F.G. Cicero - Italy</i>
11.00 - 11.30	Clinical evidence <i>M. Pirro - Italy</i>
11.30 – 11.45	Discussion
11.45 – 12.15	Coffee Break
12.15 – 12.45	Non-HDL cholesterol <i>L. Tokgözoğlu - Turkey</i>
12.45 – 13.15	Addressing residual CV risk <i>A. Mello e Silva - Portugal</i>
13.15 – 13.30	Discussion
13.30 – 14.45	Buffet lunch

14.45 – 15.15	Statin potency <i>E. Bruckert - France</i>
15.15 – 15.45	Combination therapy <i>L. Tokgözoğlu - Turkey</i>
15.45 – 16.15	PCSK9, a new therapeutic target <i>E. Bruckert - France</i>
16.15 – 16.30	Discussion
16.30 – 16.45	Meeting wrap-up <i>L. Tokgözoğlu - Turkey</i>

SUNDAY, JUNE 4

Endothelium and atherosclerosis: how to evaluate endothelial function

9.00-9.10	Introduction <i>L. Tokgözoğlu - Turkey</i>
9.10-9.30	FMD and cfPWV: the scientific rationale <i>M. Pirro - Italy</i>
9.30-10.10	Automatic detection of endothelial reactivity and arterial stiffness: practical tests <i>A.F.G. Cicero - Italy</i>
10.10-10.20	Conclusions <i>A.L. Catapano - Italy</i>